Investigators said 47 percent of patients receiving Simponi 50 mg and 51 percent of patients receiving Simponi 100 mg maintained clinical response through week 54 compared with 31 percent of patients on placebo (p = 0.01 and p < 0.001, respectively

Results from the first presentation showed that the incidence of platelet counts below the lower limit of normal was significantly lower in patients receiving tedizolid vs. Zyvox (linezolid, Pfizer Inc.), while the second presentation highlighted that tedizolid generated similar exposure in adolescent patients as in adults in both oral and I.V

patients receiving placebo (40 percent vs. 24 percent

The company reported data from a midstage trial in June, showing that second-line HCC patients receiving tivantinib as a monotherapy attained median overall survival of 7.2 months vs. 3.8 months for those on placebo...Janssen Research & Development Infectious Diseases – Diagnostics BVBA, of Beerse, Belgium, a unit of Johnson & Johnson, said results from the OPTIMIZE Phase III trial of Incivo (telaprevir) showed noninferior sustained virological response rates in previously untreated genotype 1

Patients receiving a higher dose of DPX-Survivac in combination with cyclophosphamide produced immune responses after only one vaccination and generally exhibited higher antigen-specific immunity than those receiving the combination with a lower dose, suggesting dose-related activity...Additional results showed that patients receiving the vaccine without cyclophosphamide were capable of producing antigen-specific immune responses

Sophiris Bio Inc., of La Jolla, Calif., released top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia in a Phase IIb study

Intarcia Therapeutics Inc., of Hayward, Calif., reported an analysis of Phase II data showing that two doses of ITCA 650, a continuous subcutaneous delivery of exenatide, in patients with Type II diabetes produced a 1 percent mean reduction in HbA1c at week 12, compared to a 0.7 percent reduction for patients receiving twice-daily Byetta (exenatide, Amylin Pharmaceuticals Inc.), though a lower incidence of nausea over time was seen in the 20 mcg/day dose of ITCA 650 vs

Acacia Pharma Ltd., of Cambridge, UK, reported results from its Phase IIa study of APD403 for the prevention of acute nausea and vomiting in cancer patients receiving cisplatin, with initial exploratory cohorts showing that single-agent APD403 had encouraging benefit, especially in controlling nausea

There also were consistent trends toward reduction in pain scores and the incidence of nausea and vomiting in patients receiving Caldolor, and no safety concerns were observed during the study

The study, dubbed Abili-T, is expected to enroll 180 patients, with each patient receiving two annual courses of Tcelna treatment, consisting of five subcutaneous injections per year

Celgene International Sàrl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said its Phase III PALACE-2 and PALACE-3 studies of apremilast in psoriatic arthritis demonstrated statistical significance for the primary endpoint of ACR20 at week 16 in patients receiving both 20-mg and 30-mg doses

Patients receiving the naloxone spray achieved the study's primary endpoint with a statistically significant reduction in time spent per week binge eating compared with patients on placebo

Osiris Therapeutics Inc., of Columbia, Md., said interim one-year results from its 220-patient Phase II trial testing Prochymal (remestemcel-L) in patients experiencing first-time acute myocardial infarction showed that those receiving Prochymal had significantly less cardiac hypertrophy, as measured by cardiac MRI, compared to patients receiving placebo (p < 0.05

However, a secondary endpoint of objective response rate showed statistically significant benefit for patients receiving belinostat...Patients receiving a treatment regimen that included belinostat had 43.2 percent objective response rate, compared to those receiving the comparator regimen

Patients receiving lorcaserin lost 4.5 percent to 5 percent of their initial body weight, compared to 1.5 percent for those on placebo...The greatest improvements in lung function were observed in patients receiving 600 mg of VX-809, the highest dose evaluated, plus Kalydeco

While the trial was not powered for statistical significance related to efficacy, patients receiving intravenous infusions of KB001 tended to have better clinical outcomes, with 33.3 percent of patients receiving the 3 mg/kg dose and 42 percent of patients receiving the 10 mg/kg dose alive at day 28 and free of Pa infection, compared to 20 percent of patients in the placebo group

Treatment involved the patient receiving five injections in the cervical (upper back) region of the spinal cord, in addition to the 10 he received previously in the lumbar region of the spine, for a total of 15 injections

Bristol-Myers Squibb Co., of New York, reported six-year follow-up results from a Phase III trial of Sprycel (dasatinib) in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia adult patients resistant or intolerant to Glivec (imatinib, Novartis AG), demonstrating a progression-free survival rate of 49.3 percent and an overall survival rate of 71 percent for patients receiving dasatinib, with 6 percent of patients progressing to accelerated or blast phase of the study at six

Of patients receiving insulin glargine, 58 percent were free of symptomatic hypoglycemic episode throughout the study